Editorial: Quantitative imaging methods and analysis in Alzheimer's disease assessment

Editorial: Quantitative imaging methods and analysis in Alzheimer's disease assessment

Bibliographic Details
Main Authors:	Stephanos Leandrou, Deqiang Qiu, Constantino Carlos Reyes-Aldasoro
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Aging Neuroscience
Subjects:	Alzheimer's disease quantitative imaging machine learning PET CSF gene
Online Access:	https://www.frontiersin.org/articles/10.3389/fnagi.2023.1340877/full

Similar Items

Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers
by: Petrice M. Cogswell, et al.
Published: (2021-01-01)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
by: Rik Ossenkoppele, et al.
Published: (2021-08-01)

Functional Correlates of Microglial and Astrocytic Activity in Symptomatic Sporadic Alzheimer’s Disease: A CSF/<sup>18</sup>F-FDG-PET Study
by: Chiara Giuseppina Bonomi, et al.
Published: (2023-02-01)

Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia
by: Giulia Giacomucci, et al.
Published: (2021-01-01)

Corrigendum: Assessment of Alzheimer's Disease Based on Texture Analysis of the Entorhinal Cortex
by: Stephanos Leandrou, et al.
Published: (2020-10-01)

Protein Biomarkers for the Diagnosis of Alzheimer’s Disease at Different Stages of Neurodegeneration
by: Mar Pérez, et al.
Published: (2020-09-01)

Quantitative susceptibility mapping as an imaging biomarker for Alzheimer’s disease: The expectations and limitations
by: Yuto Uchida, et al.
Published: (2022-08-01)

Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease
by: Kazushi Suzuki, et al.
Published: (2020-01-01)

Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer’s disease
by: Tengfei Guo, et al.
Published: (2020-08-01)

Quantitative Analysis of Synthetic Magnetic Resonance Imaging in Alzheimer’s Disease
by: Baohui Lou, et al.
Published: (2021-04-01)

Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes
by: Tiziana Carandini, et al.
Published: (2019-10-01)

Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer’s disease
by: Yanaika S. Hok-A-Hin, et al.
Published: (2023-05-01)

Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals
by: Xue‐Ning Shen, et al.
Published: (2021-01-01)

CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease
by: Vasileios Papaliagkas, et al.
Published: (2023-05-01)

PET NEMA IQ Phantom dataset: image reconstruction settings for quantitative PET imaging
by: Habibeh Vosoughi, et al.
Published: (2021-08-01)

Is the Brain Undernourished in Alzheimer’s Disease?
by: Roberto Aquilani, et al.
Published: (2022-04-01)

Interaction between Cognitive Reserve and Biomarkers in Alzheimer Disease
by: Elena Carapelle, et al.
Published: (2020-08-01)

Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease
by: Sonia Monge-García, et al.
Published: (2023-05-01)

Review of Quantitative Methods for the Detection of Alzheimer’s Disease with Positron Emission Tomography
by: Jarrad Perron, et al.
Published: (2022-11-01)

Altered TIMP-3 Levels in the Cerebrospinal Fluid and Plasma of Patients with Alzheimer’s Disease
by: Jung Hyun Park, et al.
Published: (2022-05-01)

Development of a potential PET probe for HDAC6 imaging in Alzheimer's disease
by: Ping Bai, et al.
Published: (2022-10-01)

Optimising quantitative 90Y PET imaging: an investigation into the effects of scan length and Bayesian penalised likelihood reconstruction
by: Nathaniel P. Scott, et al.
Published: (2019-05-01)

Metals in Imaging of Alzheimer’s Disease
by: Olga Krasnovskaya, et al.
Published: (2020-12-01)

Distinct CSF biomarker-associated DNA methylation in Alzheimer’s disease and cognitively normal subjects
by: Wei Zhang, et al.
Published: (2023-04-01)

Frontal presentation of Alzheimer's disease: A series of patients with biological evidence by CSF biomarkers
by: Leonardo Cruz de Souza, et al.

Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross‐platform validation study
by: Yanaika S. Hok‐A‐Hin, et al.
Published: (2023-07-01)

The Combination of Functional and Structural MRI Is a Potential Screening Tool in Alzheimer’s Disease
by: Chun-Chao Huang, et al.
Published: (2018-09-01)

Chemokines in patients with Alzheimer's disease: A meta-analysis
by: Hecheng Wang, et al.
Published: (2023-03-01)

Exacerbated CSF abnormalities in younger patients with Alzheimer's disease
by: Julien Dumurgier, et al.
Published: (2013-06-01)

Is liquid biopsy mature enough for the diagnosis of Alzheimer’s disease?
by: Xun Gong, et al.
Published: (2022-08-01)

First-in-human use of 11C-CPPC with positron emission tomography for imaging the macrophage colony-stimulating factor 1 receptor
by: Jennifer M. Coughlin, et al.
Published: (2022-09-01)

An Algorithm for Preclinical Diagnosis of Alzheimer's Disease
by: Tapan K. Khan
Published: (2018-04-01)

Neurophysiological Markers of Alzheimer’s Disease: Quantitative EEG Approach
by: Una Smailovic, et al.
Published: (2019-12-01)

CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer’s Disease
by: Azadeh Karami, et al.
Published: (2019-10-01)

Role of Body-Fluid Biomarkers in Alzheimer’s Disease Diagnosis
by: Thuy Trang Nguyen, et al.
Published: (2020-05-01)

Low Cerebrospinal Fluid Levels of Melanotransferrin Are Associated With Conversion of Mild Cognitively Impaired Subjects to Alzheimer’s Disease
by: Azhaar Ashraf, et al.
Published: (2019-03-01)

An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer’s disease
by: Christopher Clark, et al.
Published: (2021-04-01)

A Novel Automated Chemiluminescence Method for Detecting Cerebrospinal Fluid Amyloid-Beta 1-42 and 1-40, Total Tau and Phosphorylated-Tau: Implications for Improving Diagnostic Performance in Alzheimer’s Disease
by: Marina Arcaro, et al.
Published: (2022-10-01)

18F-Florbetaben Amyloid PET Imaging: A Chinese Study in Cognitive Normal Controls, Mild Cognitive Impairment, and Alzheimer’s Disease Patients
by: Yan Chang, et al.
Published: (2020-07-01)

Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for Alzheimer's disease in a mixed memory clinic population
by: Helena Sophia Gleerup, et al.
Published: (2021-05-01)